Mankind Pharma announced on March 18, 2026, the acquisition of the Rivotril brand for the Indian market from Roche. Rivotril, the innovator brand for clonazepam, is widely used for neurological and psychiatric conditions. This strategic move reinforces Mankind’s focus on chronic and Central Nervous System (CNS) therapies, adding a ‘Textbook’ brand with strong specialist recall to its existing neuro portfolio and setting a platform for future line extensions.
Mankind Pharma Strengthens Chronic Therapy Focus with Key Acquisition
Mankind Pharma Limited announced today, March 18, 2026, the successful acquisition of the Rivotril brand, including exclusive rights for manufacture, market, and distribution in India, from Roche. Rivotril is recognized as the innovator/reference brand for clonazepam, frequently prescribed for managing neurological and psychiatric conditions.
This strategic purchase directly aligns with Mankind Pharma’s growing emphasis on chronic therapies and specialty segments. Rivotril is specifically categorized as a ‘Textbook’ brand, boasting a strong clinical legacy and high recall among specialists, thereby complementing and strengthening Mankind’s existing Central Nervous System (CNS) therapy portfolio.
Strategic Rationale and Future Outlook
- Acquires exclusive rights to manufacture, market, and distribute Rivotril in India.
- Adds a clonazepam Textbook brand with strong clinical legacy and specialist recall.
- Strengthens Mankind Pharma’s strategic focus on chronic and CNS therapies.
- Creates a platform for future expansion through potential line extensions.
Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, stated that the acquisition is aligned with the strategy to enhance presence in chronic and specialty areas. He highlighted the opportunity to build on this platform through potential line extensions to address evolving patient and physician needs within the CNS therapy area. Mankind intends to leverage its nationwide distribution network and large field force, which engages with over 5 lakh doctors, to ensure wider access to the product.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is a major Indian pharmaceutical company focused on the domestic market. The company operates across both pharmaceutical formulations and consumer healthcare sectors. Its therapeutic areas span anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN, and respiratory products, with a clear strategy to increase its chronic presence. Mankind operates 32 manufacturing facilities in India and supports its operations with 6 dedicated R&D facilities staffed by more than 730 scientists.
Source: BSE
